Individuals are advised to discontinue use of the affected lots immediately and return the product to the point of purchase for replacement. Several lots of intravenous and subcutaneous immune ...

HyQvia is the only up to once monthly (every 2, 3 or 4 weeks) immunoglobulin subcutaneous infusion ... therapy after stabilization with intravenous immunoglobulin (IVIG) to prevent relapse of ...

Intravenous immunoglobulin (IVIG) is a type of medication used to treat people with immunodeficiencies, when the immune ...

Due to the autoimmune etiology of this disorder, IV immunoglobulin (IVIg) or plasma exchange (PE) are the first-line treatments in addition to management of ventilatory failure. IVIg is more ...

The following is a summary of “Rituximab combined with intravenous immunoglobulin in autoimmune diseases: a systematic review ...

Nobile-Orazio and colleagues (2012) compared two of the more commonly used therapies for CIDP: IV immunoglobulin (IVIg) and IV methylprednisolone. The authors performed a multicenter, randomized ...

Guselkumab is the first IL-23 inhibitor approved for Crohn's disease with subcutaneous and intravenous options, targeting inflammation by blocking IL-23 and binding to CD64. The GRAVITI study ...

they were randomized 1:1 to receive either subcutaneous or intravenous darbepoetin alfa once a week for 20 weeks before being crossed over to the other study regimen for a further 20 weeks.

CNW/ - Takeda Canada Inc. (Takeda) is pleased to announce that Health Canada has expanded the marketing authorization for HyQvia® (normal ...